Opioid use disorder (OUD) is a chronic relapsing condition characterized by a problematic pattern of heavy, uncontrolled opioid use. In the United States, OUD usually involves consumption of either: licensed prescription painkillers such as oxycodone, hydromorphone, or illicit street drugs such as heroin and synthetic analogues such as fentanyl. Recently, the US prevalence of OUD has reached epidemic levels. During 2015, approximately 2.1m and 0.59m individuals had OUD associated with prescription painkillers and heroin respectively (0.8 and 0.2 per 100 persons, CDC figures). Past year use numbers are as high as 13-15m people (US) and 1.3m (EU). OUD has caused a massive surge in the number of US hospitalizations, emergency department visits and overdose deaths.
The 2016 US figure of ~42,000 overdose deaths was the highest on record. OUD is lowering the life-expectancy of the average American and has significant socio-economic impact.
Medication-assisted therapy (MAT) treatment involving methadone (OTP only), buprenorphine and naltrexone, in combination with psychosocial counselling, can stabilize the opioid user either through detoxification or maintenance strategies. However, these treatments have strong safety considerations and are associated with high relapse or discontinuation. Moreover, only a fraction of opioid users initiate therapy. New interventions are desperately needed. Opioid hapten-based conjugated vaccine technologies have shown promising effects in preclinical models. Ideally, an OUD vaccine should block the addictive and toxic effects of opioids decreasing patient relapse, possibly in combination with existing therapies.
An OUD vaccine could be safer, have a longer efficacy duration and possibly better compliance than existing small molecule therapies.
This MarketVIEW product consists of a detailed Executive presentation (~140 .pdf slides) and comprehensive MS-Excel workbook (.xls) which forecast the potential commercial value/volume of an OUD vaccine across 8 major western markets to 2045. Three scenarios have been modelled which explore vaccine uptake at various access points along the patient treatment continuum. A thorough situation review (global epidemiology) is included along with discussion of current treatments, prevention strategies, major R&D initiatives, and competitive environment. Vaccine technologies are reviewed along with TPP generation, pricing considerations and all modelling assumptions.
This study is designed to inform any party wishing to understand and seek justification for the business case of this important vaccine.
THIS PRODUCT IS A SUMMARY PRESENTATION (~140 slides, .pdf) + MODEL